Abstract Number: 1841 • ACR Convergence 2025
Differential metabolomic signatures along lupus nephritis spectrum
Background/Purpose: Lupus nephritis (LN) is a common feature in systemic lupus erythematosus (SLE) affecting up to 50% of the individuals with this disease. The gold…Abstract Number: 1761 • ACR Convergence 2025
The Application of SLE Patient-derived PBMC-induced Mouse Model in Preclinical Pharmacological Studies
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder characterized by the production of autoantibodies targeting nuclear antigens, immune complex deposition, and chronic inflammation…Abstract Number: 1698 • ACR Convergence 2025
X Chromosome DNA Methylation Changes Suggest Epigenetic Contributions to Immune Dysregulation in Male Lupus
Background/Purpose: DNA methylation plays a critical role in the pathogenesis of lupus. Although most epigenetic studies have focused on autosomal regions, the X chromosome remains…Abstract Number: 1551 • ACR Convergence 2025
Disease Burden and Treatment Preferences for Systemic Lupus Erythematosus: Results from a Global Real-World Survey
Background/Purpose: As new treatment options for systemic lupus erythematosus (SLE) become available, understanding patient burden and preferences is key to optimizing shared decision-making. This study…Abstract Number: 1533 • ACR Convergence 2025
Belimumab Is Associated with Early Improvement in Disease Activity Measures Among Patients with Systemic Lupus Erythematosus in the US
Background/Purpose: Belimumab (BEL), a B-cell modulator mAb that selectively inhibits soluble B-lymphocyte stimulator and reduces autoreactive B cells that drive lupus disease activity, is approved…Abstract Number: 1514 • ACR Convergence 2025
Serum Antigenome Profiling Reveals Diagnostic Models for Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) exhibits profound clinical and pathogenic heterogeneity, complicating diagnosis and treatment. Identifying subtype-specific biomarkers might intrinsically link to organ involvement.Methods: Patients…Abstract Number: 1491 • ACR Convergence 2025
Feasibility of Extrarenal Systemic Lupus Erythematosus Disease Modification in GLADEL 2.0, a Latin American Cohort
Background/Purpose: The concept of disease modification (DM) has been recently introduced to improve the long-term care of patients (pts) with SLE. DM is defined as…Abstract Number: 1475 • ACR Convergence 2025
Humoral immune responses to real-world recombinant zoster vaccination in systemic lupus erythematosus
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk for herpes zoster (HZ) and its complications. Exposure to immunosuppressants (IS) at the time…Abstract Number: 1285 • ACR Convergence 2025
Investigating the Relationship Between Brain Injury Markers and Brain Volume in Children with Systemic Lupus Erythematosus and Healthy Controls
Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) are at high risk for neuropsychiatric involvement as disease onset typically occurs during the critical period of…Abstract Number: 1179 • ACR Convergence 2025
Efficacy and Safety of Ruxolitinib in Adult Patients With Refractory Connective Tissue Disease-Associated Macrophage Activation Syndrome
Background/Purpose: Macrophage activation syndrome (MAS) is a rare and life-threatening complication of connective tissue diseases (CTDs), with approximately 30% of cases being refractory to standard…Abstract Number: 1009 • ACR Convergence 2025
Pregnancy Outcomes and Comorbidities Among Individuals with Systemic Lupus Erythematosus: A Nationwide Study Using Publicly Funded Health Insurance Claims Data
Background/Purpose: Individuals with SLE are at increased risk for pregnancy complications such as preeclampsia and preterm delivery. As SLE is commonly diagnosed and active during…Abstract Number: 0934 • ACR Convergence 2025
The Use Of Preclinical Models To Understand Drivers Of Lupus Pathogenesis
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, multisystem autoimmune disease with a prevalence of 1.4-15.13/100,000 adults globally. SLE is highly heterogenous and can involve…Abstract Number: 0663 • ACR Convergence 2025
iPSC-Derived Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy shows promise in autoimmune disease. However, autologous CAR T-cell therapy is limited by prolonged pre- and…Abstract Number: 0639 • ACR Convergence 2025
Kidney Transplantation In Lupus Nephritis. Multicenter Study Of 103 Patients
Background/Purpose: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE) affecting to 40-60% of SLE. End-stage renal disease (ESRD) occurs in up…Abstract Number: 0620 • ACR Convergence 2025
The usefulness of neutrophil-to-lymphocyte ratio as a biomarker to predict lupus flares in patients under remission
Background/Purpose: Remission in Systemic Lupus Erythematosus (SLE) is described by the Definition of Remission in SLE (DORIS), but it is hardly achieved in clinical practice,…
ACR Meeting Abstracts